Top Market Data Stories


Comment & Analysis »

GlobalData Healthcare

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data

On February 6, Innate Pharma announced that the randomized, placebo-controlled, Phase II EffiKIR trial (NCT01687387) evaluating lirilumab as a single-agent maintenance treatment in elderly...

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data
GlobalData Healthcare

When faster is not better: the 'surrogate' example

When faster is not better: the 'surrogate' example
GlobalData Healthcare

Positive Phase IIb results position Synthetic Biologics’ Ribaxamase as serious contender for C. difficile Prophylaxis

Positive Phase IIb results position Synthetic Biologics’ Ribaxamase as serious contender for C. difficile Prophylaxis
GlobalData Healthcare

ImmunoGen is poised to solve a major unmet medical need in ovarian cancer

ImmunoGen is poised to solve a major unmet medical need in ovarian cancer
GlobalData Healthcare

PD-1s show early promise in melanoma brain metastases

PD-1s show early promise in melanoma brain metastases

Company Releases »

ePAT Automated Lab Reactor Optimised for 24/7 Data Capture

SYSTAG Systems Technik
ePAT Automated Lab Reactor Optimised for 24/7 Data Capture

Optimising Development Resources for Efficient Product Development

SYSTAG Systems Technik
Optimising Development Resources for Efficient Product Development

Customized Project Management and Leadership Development Courses

Successful Strategies International Customized Project Management and Leadership Development Courses

Validated Metal Analysis

Pfanstiehl
Validated Metal Analysis

Benefits of Trehalose

Pfanstiehl Benefits of Trehalose

Market Data Insights »

Companies »